Department of Neurology, the First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, People's Republic of China.
Department of Nuclear Medicine, the First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, 110001, Liaoning, People's Republic of China.
Ann Nucl Med. 2021 Feb;35(2):139-147. doi: 10.1007/s12149-020-01566-4. Epub 2021 Jan 18.
Alzheimer's disease (AD) is on the rise all over the world, and brings with it great challenges to medical care and heavy burdens to family and society. Accurate diagnosis and differential diagnosis are of great importance. Tau positron emission tomography (PET) might offer novel insights and be of great assistance in monitoring disease progression and supporting the differential diagnosis. F-AV-1451, as the first Tau PET imaging agent approved by the Food and Drug Administration (FDA), has been of great potential in clinical trials. Here, we reviewed the synthesis and characteristics of F-AV-1451 and its role in monitoring AD progression and supporting the differential diagnosis.
阿尔茨海默病（AD）在全球呈上升趋势，给医疗保健带来了巨大挑战，给家庭和社会带来了沉重负担。准确的诊断和鉴别诊断非常重要。tau 正电子发射断层扫描（PET）可能提供新的见解，并在监测疾病进展和支持鉴别诊断方面提供很大帮助。F-AV-1451 作为第一个获得食品和药物管理局（FDA）批准的 Tau PET 成像剂，在临床试验中具有很大的潜力。在这里，我们回顾了 F-AV-1451 的合成和特性及其在监测 AD 进展和支持鉴别诊断中的作用。
